间变性淋巴瘤激酶克隆号1A4抗体在儿童髓母细胞瘤中的表达及其意义

目的探讨间变性淋巴瘤激酶(ALK)克隆号1A4抗体在儿童髓母细胞瘤中的表达及意义。方法采用NanoString技术和测序技术对浙江大学医学院附属儿童医院2014至2017年诊治的44例儿童髓母细胞瘤标本进行分子分型鉴定,同时应用免疫组织化学EnVision二步法检测ALK在44例髓母细胞瘤整张切片中的表达,统计分析蛋白表达与分子分型的关系。结果患者年龄范围0.5~13.0岁,平均年龄5.8岁。男性28例,女性16例。经典型31例,促纤维增生/结节型5例,广泛结节型3例,大细胞/间变型5例。44例儿童髓母细胞瘤除3例无确切划分亚型外,其余41例中5例为WNT型,12例为SHH型,9例为Group 3型,15例为Group 4型。44例肿瘤组织中13例ALK免疫组织化学阳性,阳性率为29.5%,其中强阳性6例、弱阳性7例。ALK蛋白表达与WNT型相关(P<0.01)。WNT型中特征性出现核旁点状阳性。结论ALK克隆号1A4免疫组织化学可辅助儿童髓母细胞瘤分子分型,强阳性且出现核旁点状阳性提示WNT亚型。     

酰基缩肽1经SHH通路下调Gli和Bcl-2表达诱导肾癌细胞凋亡

目的探讨酰基缩肽1(ADEP1)对肾癌细胞凋亡及SHH信号通路相关蛋白Gli-1和Bcl-2表达的影响。方法 50μmol/L ADEP1处理肾癌ACHN细胞和769-P细胞48 h,采用光学显微镜观察细胞凋亡的细胞形态学和细胞核形态变化,MTT法检测细胞增殖,实时定量PCR(qRT-PCR)检测SHH信号通路SHH和Gli-1 mRNA的表达,Western blot法检测Gli-1和Bcl-2蛋白的表达。结果 ADEP1可诱导肾癌细胞发生凋亡,降低SHH和Gli-1 mRNA表达,以及Gli-1和Bcl-2蛋白的表达。结论ADEP1可通过抑制SHH信号通路相关蛋白表达,诱导肾癌细胞发生凋亡。     

儿童髓母细胞瘤的分子遗传学及临床研究进展

髓母细胞瘤(medulloblastoma,MB)是一种常见于儿童后颅窝的恶性胚胎性神经上皮肿瘤.WHO(2016)中枢神经系统肿瘤分类将MB分为4个主要的分子亚型:WNT、SHH、Group3和Group4,这些亚型具有显著异质性.深入了解MB各亚型的组织学及分子特征,对个体化诊治、预后评估具有重要意义.该文就MB的...     

Sonic hedgehog mRNA及其蛋白在大肠癌的表达及其临床意义

目的 探讨大肠癌中Hedgehog信号通路相关基因Sonic hedgehog(SHH)的表达及其临床意义.方法 应用RT-PCR及免疫组织化学法(Envison二步法)检测本院2008年12月至2009年4月收集的43例大肠癌组织和距离癌10 cm以上的癌旁组织的SHHmRNA及蛋白的表达情况,并与20例非肠癌患者的正常大肠组织对照,分析其与大肠癌患者临床和病理各变量的相关性.结果 凝胶成像分析显示阳性表达的样本SHH mRNA片段大小为280 bp,与理论值相符,未表达的样本则未见相应条带.大肠癌组织SHHmRNA表达阳性率为27.9%(12/43),与癌旁组织的18.6%(8/43)差异无统计学意义(P＞0.05),但均显著高于正常大肠黏膜的0%(0/20)(均P＜0.05).SHH mRNA在大肠癌组织的表达强度显著高于癌旁组织(P＜0.05),在正常大肠黏膜则未见其表达.免疫组织化学显示SHH蛋白在大肠癌组织和癌旁组织均有阳性表达,细胞膜及胞质内出现棕黄褐色颗粒,背景不着色;正常大肠黏膜阴性表达.SHH蛋白在大肠癌组织的表达阳性率显著高于正常大肠黏膜[25.6%(11/43)比0%(0/20),P＜0.05],在大肠癌组织与癌旁组织、癌旁组织与正常大肠黏膜的表达阳性率差异则无统计学意义(均P＞0.05).SHH蛋白的表达强度大肠癌组织＞癌旁组织＞正常大肠黏膜(均P＜0.05).大肠癌组织中的SHH mRNA和蛋白表达强度与患者的年龄、性别、临床分期、肿瘤部位、肿瘤浸润深度、病理分型等变量均无明显关系(均P＞0.05).结论 SHH mRNA和蛋白在大肠癌组织中表达显著增强,但与临床和病理各变量无关联.     

通过DNA甲基化测序来破译髓母细胞瘤的基因序列

表观遗传学的改变,DNA甲基化和核染色质结构的破坏,目前被认为是肿瘤发生过程中最普遍的的特征。这种现象也毫无例外的发生在儿童脑的髓母细胞瘤中。尽管从目前基因组学的研究中,对髓母细胞瘤取得较大的进展,然而四种不同分子亚型(WNT、SHH、Group 3及Group 3)间均存在许多不同的特点,许多案例仍缺乏明显的基因启动子。作者对34个人类和5个鼠类动物的髓母细胞瘤,加上8个人类和3个鼠类正常对照组进行深入分析,包括对整个基因组     

WNT4及其抑制因子SFRP1在糖尿病肾病大鼠肾组织中的表达

目的观察WNT4/β-catenin信号通路及其抑制因子分泌型卷曲相关蛋白1(SFRP1)在糖尿病肾病(DN)大鼠肾组织中的表达变化,探讨其在肾脏纤维化发生发展中的可能作用。方法将大鼠随机分为正常对照(NC)组和DN组,8只/组。尾静脉注射STZ 55 mg/kg复制IDDM模型。HE、PAS及Masson染色观察肾组织形态学结构和纤维化病变;免疫组织化学法观察WNT4和β-catenin蛋白在肾组织的表达部位;Western blot检测WNT4、SFRP1、β-catenin、p-GSK-3β、GSK-3β、CollagenⅠ、α-SMA和E-cadherin蛋白在肾组织中的表达;Real-time PCR检测WNT4及SFRP1 mRNA在肾组织中的表达。结果与NC组相比,DN组大鼠肾组织纤维化病变明显;WNT4蛋白和mRNA表达显著增多(P<0.05);β-catenin、p-GSK-3β、α-SMA和CollagenⅠ蛋白的表达显著增多(P<0.05);E-cadherin蛋白表达显著减少(P<0.05);SFRP1蛋白和mRNA表达显著下降(P<0.05)。结论在DN发病中,WNT4/β-catenin信号通路异常活化;SFRP1表达减少可能抑制该通路,促进了DN肾纤维化的发生发展。     

β-catenin和wnt-1在食管癌组织中的表达及其临床意义

研究β-catenin和wnt-1在食管癌组织中的蛋白表达水平及其与肿瘤病理参数和预后的关系。选取40例具有完整病理资料、手术切除的食管癌蜡块标本和其中10例癌旁组织,应用免疫组化方法检测其β-catenin和wnt-1的蛋白表达水平,比较β-catenin和wnt-1蛋白在组织中的表达差异,及其与食管癌各种临床病理特征和预后的关系。结果显示,β-cate-nin的表达水平与临床分期有相关性（P〈0.05）;wnt-1的表达水平与细胞分化、预后有相关性（P〈0.05）;β-catenin、wnt-1的蛋白表达水平与性别、年龄无相关性（P〉0.05）。wnt-1和β-catenin作为Wnt信号通路的相关蛋白,与食管癌的发展和预后有一定关系。     

弥漫大B细胞淋巴瘤中Wnt通路相关蛋白的表达及预后危险因素分析

目的探讨弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma, DLBCL)中Wnt通路相关蛋白的表达及预后危险因素。方法收集哈尔滨市第一医院收治的80例DLBCL组织标本和同期淋巴结良性增生组织45例。分析DLBCL组织、淋巴结良性增生组织中NKD1、β-catenin、Cyclin D1的表达及与DLBCL临床病理特征及患者预后的关系。结果 NKD1在DLBCL组织中的阳性率为18.75%,低于淋巴结良性增生组织(75.56%)(P0.05);β-catenin和Cyclin D1在DLBCL组织中的阳性率分别为78.75%、72.50%,均高于淋巴结良性增生组织(均为0)(P0.05);NKD1、β-catenin、Cyclin D1蛋白表达与DLBCL患者IPI评分、Ann Arbor分期有关,病理分型与NKD1蛋白表达有关。Cyclin D1和β-catenin的表达呈明显正相关(P0.01),NKD1和β-catenin与Cyclin D1的表达均呈明显负相关(P均0.01);NKD1阳性患者的3年生存率高于阴性者(P0.05),而β-catenin和Cyclin D1阳性患者的3年生存率低于阴性者(P0.05);β-catenin、Cyclin D1蛋白表达是影响DLBCL预后的风险因素,NKD1蛋白阳性是保护因素。结论 NKD1在DLBCL中低表达,β-catenin、Cyclin D1呈高表达,三者可作为DLBCL患者预后的独立预测因素,有望成为DLBCL的潜在治疗靶点。     

细胞周期蛋白D1(cyclinD1)及p16蛋白在肾母细胞瘤中的表达

目的　探讨细胞周期蛋白D1(cyclinD1)和p16蛋白在肾母细胞瘤中的表达、相关性及其意义。方法　应用免疫组织化学方法检测 4 2例肾母细胞瘤患者组织中cyclinD1和 p16蛋白的表达情况。结果　 4 2例中cyclinD1蛋白过表达率为 4 5 .2 3% ,p16蛋白表达缺失率为 6 9.0 4 % ,p16阳性表达与病理组织类型、患儿预后明显相关 (P <0 .0 1)阳性表达者预后好。结论　 (1) p16 -cyclinD1- pRb通路异常与肾母细胞瘤的发病机制密切相关 ,(2 )cyclinD1过表达是肿瘤发生的早期事件 ,(3) p16蛋白表达可作为判断肾母细胞瘤预后的一项指标。     

胃癌中FOXD3的表达及其与β-catenin表达的相关性

目的探讨FOXD3表达与胃癌临床病理学特征、预后及β-catenin表达的相关性。方法收集78例胃癌及癌旁组织,采用qRT-PCR法检测FOXD3 mRNA的表达,采用免疫组化EnVision法检测β-catenin的表达。结果 FOXD3 mRNA在胃癌组织中的表达量为0.146±0.036,在癌旁组织中的表达量为-0.379±0.107,上调3.35倍(P=0.001)。FOXD3表达与胃癌分化程度和Lauren分型密切相关(P0.05)。Kaplan-Meier分析结果显示,FOXD3高表达组总体生存率(overall survival, OS)比低表达组差(P=0.046)。Spearsman等级相关性分析结果显示,胃癌中FOXD3表达与β-catenin表达呈正相关(r=0.280,P=0.023)。结论 FOXD3在胃癌组织中过表达并与胃癌组织分化程度、Lauren分型及预后密切相关,FOXD3可能通过Wnt/β-catenin信号促进胃癌的发生、发展,FOXD3可能是判断胃癌预后的分子标志物。     

上皮性卵巢癌中E盒结合锌指蛋白2和转化生长因子β1的表达及其预后的关系

目的 研究上皮性卵巢癌中E盒结合锌指蛋白2(ZEB2)和转化生长因子β1(TGF-β1)的表达及预后意义.方法 采用免疫组化SP法检测52例上皮性卵巢癌、23例卵巢良性上皮性肿瘤和15例正常卵巢组织中ZEB2和TGF-β1的表达,分析二者在卵巢上皮癌中的相关性及与临床病理特征和预后的关系.结果 ZEB2和TGF-β1在上述三种组织中均定位于细胞质,其阳性表达率分别为67.3％、21.7％、13.3％和71.2％、30.4％、20.0％,差异均有统计意义(x2=21.34、18.087,p均＜0.05);ZEB2和TGF-β1在卵巢上皮癌中的表达存在正相关(rs=0.552,P＜0.05),且与分化程度、FIGO分期有关(P＜0.05),与年龄、病理类型无关(P＞0.05);ZEB2和TGF-β1表达与卵巢上皮癌患者总生存率有关(P＜0.05);COX风险比例模型显示ZEB2阳性表达是预后危险因素(OR=2.653,P＜0.05).结论ZEB2和TGF-β1可能促进上皮性卵巢癌进展,ZEB2可能作为评估预后的新指标.     

NOTUM基因在胃癌组织中的表达及临床病理意义

目的:检测NOTUM基因在胃癌组织中的表达情况,探讨其与胃癌患者的临床病理关系.方法:收集2014年10月至2015年4月在中国人民解放军总医院普通外科手术治疗的胃癌标本及正常胃黏膜组织80例,采用免疫组织化学方法检测胃癌组织及胃黏膜正常组织中NOTUM基因的表达情况,分析NOTUM基因的表达与患者的临床病理及预后的关系.采用免疫印迹检测NOTUM蛋白及β-catenin蛋白的表达量,使用SPSS进行相关性分析确定NOTUM蛋白与β-catenin蛋白之间的关系.应用Kaplan-Meier方法比较NOTUM阳性表达胃癌患者与阴性表达胃癌患者在术后生存时间的差异.分别采用Log-rank检验和Cox回归模型对可能影响预后的临床病理特征进行单因素和多因素分析.结果:胃癌组织中NOTUM基因的表达显著增加,其表达与淋巴结转移及TNM分期及预后生存相关(P＜0.05),与患者的年龄、性别、肿瘤发生部位、肿瘤大小及肿瘤病理类型无关.胃癌组织中NOTUM基因和β-catenin蛋白的表达呈正相关.在NOTUM基因表达阳性的胃癌患者的生存时间明显缩短.NOTUM基因表达可以作为影响胃癌患者生存的独立危险因素.结论:胃癌中NOTUM基因在胃癌组织中呈高表达,可作为判断胃癌患者疾病进展及预后的生物学标志物.     

CTNNB1, AXIN1 and APC expression analysis of different medulloblastoma variants

OBJECTIVES:

We investigated four components of the Wnt signaling pathway in medulloblastomas. Medulloblastoma is the most common type of malignant pediatric brain tumor, and the Wnt signaling pathway has been shown to be activated in this type of tumor.

METHODS:

Sixty-one medulloblastoma cases were analyzed for β-catenin gene (CTNNB1) mutations, β-catenin protein expression via immunostaining and Wnt signaling pathway-related gene expression. All data were correlated with histological subtypes and patient clinical information.

RESULTS:

CTNNB1 sequencing analysis revealed that 11 out of 61 medulloblastomas harbored missense mutations in residues 32, 33, 34 and 37, which are located in exon 3. These mutations alter the glycogen synthase kinase-3β phosphorylation sites, which participate in β-catenin degradation. No significant differences were observed between mutation status and histological medulloblastoma type, patient age and overall or progression-free survival times. Nuclear β-catenin accumulation, which was observed in 27.9% of the cases, was not associated with the histological type, CTNNB1 mutation status or tumor cell dissemination. The relative expression levels of genes that code for proteins involved in the Wnt signaling pathway (CTNNB1, APC, AXIN1 and WNT1) were also analyzed, but no significant correlations were found. In addition, large-cell variant medulloblastomas presented lower relative CTNNB1 expression as compared to the other tumor variants.

CONCLUSIONS:

A small subset of medulloblastomas carry CTNNB1 mutations with consequent nuclear accumulation of β-catenin. The Wnt signaling pathway plays a role in classic, desmoplastic and extensive nodularity medulloblastoma variants but not in large-cell medulloblastomas.     

The role of WNT1 mutant variant (WNT1c.677C>T) in osteogenesis imperfecta

Osteogenesis imperfecta (OI), also known as “brittle bone disease,” is a rare inherited genetic disorder characterized by bone fragility and often associated with short stature. The mutation in WNT1 causes autosomal recessive OI (AR-OI) due to the key role of WNT/β-catenin signaling in bone formation. WNT1 mutations cause phenotypes in OI of varying degrees of clinical severity, ranging from moderate to progressively deforming forms. The nucleotide change c.677C > T is one of the recurrent variants in the WNT1 alleles in Chinese AR-OI patients. To explore the effects of mutation c.677C > T on WNT1 function, we evaluated the activation of WNT/β-catenin signaling, cell proliferation, osteoblast differentiation, and osteoclast differentiation in WNT1^c.677C>T, WNT1^c.884C>A, and wild type WNT1 transfected into MC3T3-E1 preosteoblasts. Plasmids containing wild type WNT1, WNT1^c.677C>T, and WNT1^c.884C>A cDNAs were constructed. Protein levels of phosphorylation at serine 9 of GSK-3β (p-GSK-3β), GSK-3β, nonphosphorylated β-catenin (non-p-β-catenin), and β-catenin were detected with western blot. Cell proliferation was determined using MTS. BMP-2 and RANKL mRNA and protein levels were detected by qPCR and western blot. Our results showed that WNT1^c.677C>T failed to activate WNT/β-catenin signaling and impaired the proliferation of preosteoblasts. Moreover, compared to wild type WNT1, WNT1^c.677C>T downregulated BMP-2 protein expression and was exhibited a diminished capacity to suppress the RANKL protein level. In conclusion, mutation c.677C > T hindered the ability of WNT1 to induce the WNT/β-catenin signaling pathway and it affected the WNT/β-catenin pathway which might potentially contribute to hampered bone homeostasis.     

AICAR, an activator of AMPK, inhibits adipogenesis via the WNT/β-catenin pathway in 3T3-L1 adipocytes

AMP-activated protein kinase (AMPK) is known to sense the cellular energy state and regulates various cellular energy metabolism pathways through its activation by AMP, an indicator of a low-energy state. 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR), an activator of AMPK, efficiently inhibited the adipogenesis of 3T3-L1 cells. To elucidate its possible mechanism of action, the expression levels of β-catenin and other members of the WNT/β-catenin pathway were analyzed during the adipogenesis of 3T3-L1 cells in the presence or absence of AICAR. It was found that AICAR significantly enhanced β-catenin expression and its nuclear accumulation. Transfection of β-catenin small interfering RNA (siRNA) significantly prevented the effects of AICAR on the expression of various genes. The expression of the major genes of adipogenesis including the peroxisome proliferator-activated receptor (PPAR)γ, the CCAAT/enhancer binding protein (C/EPB)α, the fatty acid binding protein (FABP)4 and lipoprotein lipase (LPL), which were all reduced by AICAR treatment, were significantly recovered in β-catenin siRNA-transfected cells. Among the members of the WNT/β-catenin pathway, the expression of low density lipoprotein receptor-related protein (LRP)6, dishevelled (DVL)2 and DVL3 were significantly up-regulated by AICAR treatment, whereas the expression of AXIN was down-regulated. The present study provides compelling evidence that AICAR inhibits adipogenesis through the modulation of the WNT/β-catenin pathway.     

β-catenin与小鼠毛囊衰老性变化相关

 摘要：目的探讨β-catenin与毛囊衰老性变化的关系。方法 取老龄与年轻小鼠处于毛囊周期各阶段的皮肤,RT-PCR和Western blot检测β-catenin在mRNA和蛋白水平的表达; IF检测比较β-catenin蛋白表达在毛囊中的组织学分布。结果 老年鼠背皮的β-catenin表达相较处于同一毛囊周期阶段的年轻鼠皮肤在mRNA水平和蛋白质水平均有上调,出生后34个月的小鼠生长期皮肤中β-catenin蛋白的表达为0.9024±0.0167,显著高于出生后35天的0.8012±0.0184。 出生后34个月的小鼠静止期皮肤中β-catenin蛋白表达为0.6348±0.0241,显著高于出生后23天的0.6348±0.0241（P＜0.05）。IF检测显示β-catenin的表达集中在外根鞘和Bulge细胞,也可以观察到β-catenin的入核现象。结论β-catenin表达量上调,周期节律不明显,表达部位不同于年轻鼠可能是衰老相关性白发产生的原因之一。     

LMP1 antagonizes WNT/β-catenin signalling through inhibition of WTX and promotes nasopharyngeal dysplasia but not tumourigenesis in LMP1(B95-8) transgenic mice

Latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) can induce cell transformation and tumourigenesis, but the mechanism is not understood. Previous studies have suggested that LMP1 acts through up-regulation of cellular proliferation pathways including the Wnt/β-catenin pathway, in which β-catenin is the central effector. Increased levels of β-catenin coupled with a decrease in E-cadherin lead to reduced cell adhesion. This pathway is antagonized by WTX (Wilms' tumour gene on the X chromosome), which can promote the ubiquitination and degradation of β-catenin. In the present study, we established L2/LMP1B(95 - 8) /EGFP transgenic mice to investigate the in vivo role of LMP1. Down-regulation of WTX and E-cadherin was accompanied by increased expression of β-catenin in these mice. Even though invasive tumours did not develop, dysplasia was seen in the nasopharynx and oropharynx epithelium of these transgenic mice. Analysis of LMP1(+) , WTX(+) , and LMP1 siRNA silenced HNE-1 cell lines demonstrated that WTX could exert a dominant role in LMP1-mediated WNT/β-catenin pathway regulation. This study indicates that LMP1 antagonizes the WNT/β-catenin pathway by inhibiting WTX, and this reduction in WTX is associated with epithelial dysplasia via regulation of the WNT/β-catenin pathway molecules E-cadherin and β-catenin. Further studies are required for a better understanding of the relationship between LMP1-mediated antagonization of the WNT/β-catenin pathway and tumourigenesis.     

WNT/β-catenin pathway is modulated in asthma patients and LPS-stimulated RAW264.7 macrophage cell line

In the present study, we investigated the possibility that the WNT/β-catenin pathway plays a role in inflammatory responses both in an human inflammatory condition and in an in vitro inflammation model. First, we analyzed gene expression patterns of the peripheral blood cells from asthma patients compared with those from normal subjects using microarray analyses. We found that intracellular signaling molecules of the WNT/β-catenin pathway were significantly changed in asthma patients compared with the levels in the controls. Next, we determined whether major components of the WNT/β-catenin pathway were involved in the lipopolysaccharide (LPS)-induced inflammatory response of the RAW264.7 macrophage cell line. Among the members of WNT/β-catenin pathway, the protein levels of low-density lipoprotein receptor-related protein (LRP) 6, dishevelled (DVL) 2, and AXIN1, which were measured using western blotting, did not significantly change in the presence of LPS. In contrast, the LPS induced a rapid phosphorylation of glycogen synthase kinase (GSK) 3β and accumulation of β-catenin protein. It was found that β-catenin plays a significant role in the LPS-induced inflammatory response through the performance of small interfering RNA (siRNA) transfection experiments. The mRNA level of IL-6 was significantly elevated in β-catenin siRNA-transfected cells compared with that in control siRNA-transfected cells after LPS treatment. Furthermore, nuclear factor-κB (NF-κB) activity was also significantly increased in β-catenin siRNA-transfected cells compared with the level seen in control siRNA-transfected cells. Taken together, these results suggest that β-catenin plays a role as a negative regulator, preventing the overproduction of inflammatory cytokines such as IL-6 in LPS-induced inflammatory responses.     

shRNA沉默β-catenin基因表达对人食管癌细胞生物学特性的影响

目的 构建稳定抑制β-catenin表达的食管癌细胞克隆,观察shRNA介导的β-catenin基因沉默对人食管癌细胞生物学特性的影响,为以β-catenin为靶的食管癌基因治疗提供理论和实验依据.方法 通过细菌转化、酶切、测序鉴定和基因重组等方法构建针对β-catenin的RNA干扰质粒pGen-3-CTNNB1和阴性对照质粒pGen-3-con.利用脂质体介导转染技术转染人食管癌细胞系Eca-109,经G418筛选得到稳定抑制β-catenin表达的食管癌细胞模型(pGen-3-CTNNB1细胞);逆转录聚合酶链反应(RT-PCR)、细胞免疫荧光和Western blot检测RNA干扰组(pGen-3-CTNNB1)、阴性对照组(pGen-3-con)及未转染组(Eca-109)3组细胞中β-catenin的表达;建立裸鼠皮下移植瘤模型,观察抑制β-catenin表达在活体内对肿瘤细胞生长能力的影响,免疫组织化学检测移植瘤组织中β-catenin的表达水平;体外浸润实验、迁移实验检测各组细胞的侵袭转移能力.结果 成功构建了针对β-catenin基因的RNA干扰载体pGen-3-CTNNB1,建立了稳定抑制β-catenin基因表达的食管癌细胞模型;与阴性对照组[(1.18±0.13)g]和未转染组[(1.38±0.21)g]比较,RNA干扰组[(0.42±0.09)g]移植瘤重量明显减轻(P＜0.05);瘤组织中β-catenin的表达水平明显降低;抑制β-catenin基因表达后,食管癌细胞的浸润能力显著降低,阴性对照组浸润细胞数为(81±5)个/HPF、未转染组为(77±6)个/HPF、RNA干扰组为(41±4)个/HPF(P＜0.01);迁移能力也显著下降,阴性对照组迁移细胞数为(73±5)个/HPF、未转染组为(69±5)个/HPF、RNA干扰组为(38±4)个/HPF(P＜0.05).结论 在人食管癌细胞Eca-109中存在β-catenin表达异常和Wnt信号通路的异常激活,抑制β-catenin基因的表达可以在裸鼠体内显著抑制食管癌细胞的生长,并降低其侵袭转移的能力.